[go: up one dir, main page]

MX9207150A - METHOD AND COMPOSITIONS TO REDUCE THE RESISTANCE TO MULTIPLE PHARMACS. - Google Patents

METHOD AND COMPOSITIONS TO REDUCE THE RESISTANCE TO MULTIPLE PHARMACS.

Info

Publication number
MX9207150A
MX9207150A MX9207150A MX9207150A MX9207150A MX 9207150 A MX9207150 A MX 9207150A MX 9207150 A MX9207150 A MX 9207150A MX 9207150 A MX9207150 A MX 9207150A MX 9207150 A MX9207150 A MX 9207150A
Authority
MX
Mexico
Prior art keywords
compositions
resistance
pharmacs
reduce
human
Prior art date
Application number
MX9207150A
Other languages
Spanish (es)
Inventor
John S Coon
Original Assignee
Rush Presbyterian St Luke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush Presbyterian St Luke filed Critical Rush Presbyterian St Luke
Publication of MX9207150A publication Critical patent/MX9207150A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención incluye métodos y composiciones para reducir o eliminar la resistencia a múltiples fármacos en cánceres de seres humanos o animales. De conformidad con el método y la composición de la presente invención, se administra un éster anfipático no iónico de un ácido graso a un paciente, donde un cáncer humano o de animal exhibe una resistencia a múltiples fármacos, para el agente quimioterapéutico.The present invention includes methods and compositions for reducing or eliminating multi-drug resistance in human or animal cancers. In accordance with the method and composition of the present invention, a nonionic fatty acid amphipathic ester is administered to a patient, where a human or animal cancer exhibits multi-drug resistance, for the chemotherapeutic agent.

MX9207150A 1991-12-10 1992-12-10 METHOD AND COMPOSITIONS TO REDUCE THE RESISTANCE TO MULTIPLE PHARMACS. MX9207150A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80518691A 1991-12-10 1991-12-10
US98276692A 1992-12-07 1992-12-07

Publications (1)

Publication Number Publication Date
MX9207150A true MX9207150A (en) 1993-12-01

Family

ID=27122756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9207150A MX9207150A (en) 1991-12-10 1992-12-10 METHOD AND COMPOSITIONS TO REDUCE THE RESISTANCE TO MULTIPLE PHARMACS.

Country Status (8)

Country Link
EP (1) EP0616493A4 (en)
JP (1) JPH07502274A (en)
CN (1) CN1076358A (en)
AU (1) AU3243393A (en)
CA (1) CA2125279A1 (en)
IL (1) IL104063A0 (en)
MX (1) MX9207150A (en)
WO (1) WO1993011668A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
CA2130025A1 (en) * 1993-08-25 1995-02-26 Robert B. Peery Method of treating fungal infections
CA2190636A1 (en) * 1994-05-19 1995-11-30 John S. Coon Methods and compositions for reducing multidrug resistance
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
WO2000053231A2 (en) * 1999-03-09 2000-09-14 Protarga, Inc. Fatty acid-anticancer conjugates and uses thereof
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE10115740A1 (en) 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medical device for drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4889525A (en) * 1982-08-17 1989-12-26 Adamantech, Inc. Sensitization of hypoxic tumor cells and control of growth thereof
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4563351A (en) * 1983-08-01 1986-01-07 Forsyth Dental Infirmary For Children Self-gelling therapeutic compositions for topical application
SE8601624D0 (en) * 1986-04-11 1986-04-11 Haessle Ab NEW PHARMACEUTICAL PREPARATIONS
US4978622A (en) * 1986-06-23 1990-12-18 Regents Of The University Of California Cytophaga-derived immunopotentiator
JP2558107B2 (en) * 1986-12-18 1996-11-27 第一製薬株式会社 Topical
US4863968A (en) * 1987-04-09 1989-09-05 Merrell Dow Pharmaceuticals Inc. Methods of treating gout with chalcone derivatives
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5108989A (en) * 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair

Also Published As

Publication number Publication date
CA2125279A1 (en) 1993-06-24
EP0616493A1 (en) 1994-09-28
WO1993011668A1 (en) 1993-06-24
JPH07502274A (en) 1995-03-09
AU3243393A (en) 1993-07-19
CN1076358A (en) 1993-09-22
IL104063A0 (en) 1993-05-13
EP0616493A4 (en) 1994-11-09

Similar Documents

Publication Publication Date Title
ES2053990T3 (en) COMPOSITIONS OF ESSENTIAL FATTY ACIDS.
DE69114498D1 (en) SHORT-BED, SIMPLY UNSATURATED FATTY ACIDS, AND PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS.
IT1176916B (en) PHARMACEUTICAL OR DIETETIC COMPOSITION WITH HIGH ANTI-THROMBOTIC AND ANTI-ARTERIOSCLEROTIC ACTIVITY
DE69720787D1 (en) PHARMACEUTICAL PREPARATION CONTAINING EICOSAPENTIC ACID AND / OR STEARIDONIC ACID
PT774962E (en) USING DHA AS A PHARMACEUTICAL COMPOSITION
DE60000133D1 (en) ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS
PL261349A1 (en) Method of obtaining an incorporative complex of 7-isopropoxyisoflavone with cyclodextrin
EP0739210A4 (en) Methods and compositions for the treatment of a host with a cellular proliferative disease
SE8402560L (en) PHARMACEUTICAL COMPOSITION
ATE75397T1 (en) USE OF VITAMIN E IN THE MANUFACTURE OF PHARMACEUTICALS FOR THE NORMALIZATION OF BLOOD COAGLING IN THERAPY WITH OMEGA-3 TYPE HIGH UNSATURATED FATTY ACIDS.
ATE361066T1 (en) POLYUNSATURATED FATTY ACID NUTRITIONAL SUPPLEMENT
TW336171B (en) Pharmaceutical composition for use in the treatment of vulvar dystrophy and/or vaginal dryness
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
MX9207150A (en) METHOD AND COMPOSITIONS TO REDUCE THE RESISTANCE TO MULTIPLE PHARMACS.
US5246726A (en) Iron-containing composition and method for treatment of cancer
US5128152A (en) Iron-containing compositions and method for treating cancer
ES8102141A1 (en) 3,7-Disubstituted-3-cephem-4-carboxylic acid compounds
IE862351L (en) Pharmaceutical compositions
NO175885C (en) Process for the preparation of a salicylic acid-containing agent for the local treatment of skin diseases with peel
ES2009249A6 (en) Skin-regenerating cosmetic composition
ES8304058A1 (en) 3,7,11,15-Tetramethyl- 2,4,6,10,14-hexadecapentaenoic Acid
EP0357646A4 (en) Treatment of aged skin with oral 13-cis-retinoic acid
BE894860A (en) Prevention of breast cancer recurrence following mastectomy - by admin. of 17 alpha acyloxy 6:methyl pregna 4,6-dien 3,20:di:one
NO912890D0 (en) PREPARATION CONTAINING SALICYLIC ACID FOR TREATMENT OF SKIN DISEASES WITH EXCELLENT.
ES2052201T3 (en) RETINOIC ESTERS OF L-CLADINOSE, ITS PREPARATION PROCEDURE AND ITS USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS.